Previously, our SPORE investigators (5 projects) successfully translated their basic findings into 3 Phase 1 interventional clinical trials, a 42-patient glioma tissue analysis defining loss of a key growth regulatory mechanism and a 332 patient case-control genetic epidemiology survey defining significant associations of two HLA phenotypes with either indolent or rapid glioma progression. The themes of this, new competitive renewal SPORE application include: Anti-apoptosis Inhibition, Oncolytic Virus therapy, Antibody-mediated Therapy, Apoptosis, and Autophagy. Four translational research projects are proposed, each of which will initiate one or more interventional clinical trials within a 3- 5 year time frame. These include: 1)Targeted'Intervention of the JAK2/STAT3 Signaling Axis for Anaplastic Glioma Therapy o develop a rational basis for inhibiting the JAK2/STAT3 pathway using small molecule inhibitor drugs to improve conventional therapeutic outcomes;2) Optimized Chimeric HSV for Anaplastic Glioma Therapy will develop a clinical application for a cGMP RAID-produced chimeric herpes simplex virus is safe while significantly enhanced in its replicative properties and overall ability to infect and kill glioma cells;3) Enhancing Death Receptor Antibody Therapy for Anaplastic Gliomas will evaluate two new pro-apoptotic drugs, AT-101 and AT-406, together with a UAB developed, humanized anti-DR5 monoclonal antibody administered either intravenously or by convection enhanced delivery to induce apoptosis in tumor-associated endothelium and. glioma cells;and 4) Lysosomotropic Therapy of Anaplastic Gliomas will characterize blood-brain barrier-permeable analogues of chloroquine and fluoroquinolone that induce glioma cell autophagy. These projects will be supported by 5 Cores: 1) Administrative, 2) Brain Tumor Tissue, 3) Clinical Trials, 4) Biostatistics/Bioinformatics, and 5) Brain Tumor Animal Models. Our Career Development Program has recruited 2 new investigators to brain tumor translational research and will support up to 4 more. We will continue the: very successful Developmental Research Program that supported 15 investigators, .9 of whom were new to brain tumor research. All four of the proposed projects in this application were originally Developmental Projects. The University, School of Medicine and Comprehensive Cancer Center strongly support this SPORE application We will continue our multiple, active collaborations with other Brain Tumor SPOREs and will foster new interactions with other non-brain organ site cancer SPORE programs locally and nationally.

Public Health Relevance

Patients diagnosed with anaplastic gliomas face a dismal prognosis as overall survival has remained essentially unchanged despite more than 50 years of extensive basic and clinical science research. The principal goal of the UAB Brain Tumor SPORE is to have a positive impact on this unacceptable situation by translating the laboratory-based discoveries of four multi-disciplinary groups of scientists into novel, yet practical, Phase I clinical interventions that address the unmet need for more effective treatments.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Exploratory Grants (P20)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Program Officer
Arnold, Julia T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
Schools of Medicine
United States
Zip Code
Friedman, G K; Nan, L; Haas, M C et al. (2015) ??34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia. Gene Ther 22:348-55
Megison, Michael L; Gillory, Lauren A; Stewart, Jerry E et al. (2014) Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors. PLoS One 9:e86843
Han, Xiaosi; Zhang, Wenbin; Yang, Xiuhua et al. (2014) The role of Src family kinases in growth and migration of glioma stem cells. Int J Oncol 45:302-10
Jackson, J D; McMorris, A M; Roth, J C et al. (2014) Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines. Gene Ther 21:984-90
Ferrarese, Roberto; Harsh 4th, Griffith R; Yadav, Ajay K et al. (2014) Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. J Clin Invest 124:2861-76
Anderson, Joshua C; Duarte, Christine W; Welaya, Karim et al. (2014) Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines. Radiother Oncol 111:468-74
Roth, Justin C; Cassady, Kevin A; Cody, James J et al. (2014) Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev 25:16-27
Han, Xiaosi; Li, Rong; Zhang, Wenbin et al. (2014) Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. J Neurooncol 118:61-72
Griguer, Corinne E; Cantor, Alan B; Fathallah-Shaykh, Hassan M et al. (2013) Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme. PLoS One 8:e61035
Cassady, Kevin A; Saunders, Ute; Shimamura, Masako (2012) ???134.5 herpes simplex viruses encoding human cytomegalovirus IRS1 or TRS1 induce interferon regulatory factor 3 phosphorylation and an interferon-stimulated gene response. J Virol 86:610-4